Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aldexchem Kft has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's current prosecution is concentrated under 1 distinct examiner, which simplifies the communication channel between the applicant and the USPTO. Additionally, the portfolio is active in 1 distinct art unit, suggesting that the pending claims fall within a specific pharmaceutical classification. This concentration in the art unit helps in predicting the examination timeline based on that unit's specific backlog.
The busiest examiner for the portfolio is BAKSHI, PANCHAM, who is currently handling 1 busiest examiner pending office action. This examiner manages the company's active office actions, as there is only 1 distinct examiner for the entire portfolio. The 1 pending office action represents the total current workload for the company's legal team in this jurisdiction. This focused activity allows for a precise approach to overcoming any cited rejections. With only 1 pending office action and 1 distinct art unit, the company can devote significant resources to securing this particular patent.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAKSHI, PANCHAM | 1 | 76.7% | +30.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268030 | TRIARYL BORANE CATALYSTS AND METHOD FOR SELECTIVE HYDROSILYLATION OF ESTERS AND LACTONES USING SAID CATALYSTS | BAKSHI, PANCHAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268030 | TRIARYL BORANE CATALYSTS AND METHOD FOR SELECTIVE HYDROSILYLATION OF ESTERS AND LACTONES USING SAID CATALYSTS | BAKSHI, PANCHAM | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18268030 | TRIARYL BORANE CATALYSTS AND METHOD FOR SELECTIVE HYDROSILYLATION OF ESTERS AND LACTONES USING SAID CATALYSTS | BAKSHI, PANCHAM | 1623 | §103§112 | Final Rejection | — | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAldexchem Kft has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Pancham Bakshi has the most, with 1 of Aldexchem Kft's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.